Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Michael, Stepanavage"'
Autor:
Michael Davidson, Sherry Xueyu Liu, Philip Barter, Eliot A. Brinton, Christopher P. Cannon, Antonio M. Gotto, Jr., Elizabeth T. Leary, Sukrut Shah, Michael Stepanavage, Yale Mitchel, Hayes M. Dansky
Publikováno v:
Journal of Lipid Research, Vol 54, Iss 2, Pp 467-472 (2013)
Estimation of low-density lipoprotein cholesterol (LDL-C) using the Friedewald (FR) formula is often inaccurate when triglycerides are elevated or VLDL particle composition is altered. We hypothesized that LDL-C estimation by the FR formula and other
Externí odkaz:
https://doaj.org/article/6a2fcbd9ba29424f83ed05a6e6cfc2d9
Autor:
Russell S. Scott, Henk D. Bakker, John J.P. Kastelein, Patrice Perron, Leiv Ose, Aditi Sapre, Michael Stepanavage, Tamas Szamosi, Marie Lambert, A S Paul van Trotsenburg, Saskia de Jongh, Mary B. Tuohy, Dries Dobbelaere, M. Saborio, Barry Gumbiner, Claude Gagné, Michele Mercuri
Publikováno v:
Circulation, 106(17), 2231-2237. Lippincott Williams and Wilkins
Background— A multicenter, randomized, double-blind, placebo-controlled study was conducted to evaluate LDL cholesterol–lowering efficacy, overall safety, and tolerability and the influence on growth and pubertal development of simvastatin in a l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::397813119485b4901437c61e44e8ed3c
https://doi.org/10.1161/01.cir.0000035247.42888.82
https://doi.org/10.1161/01.cir.0000035247.42888.82
Publikováno v:
Drug Information Journal. 35:1235-1246
The intervention of most clinical therapies typically involves shifting the central tendency of a response variable. There are many analytical methods to summarize these shifts and provide inferential results for treatment differences. Differences be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1ef3c7ea55e00118585d992b24553da
https://doi.org/10.1177/009286150103500420
https://doi.org/10.1177/009286150103500420
Autor:
J.J.P. Kastelein, Leiv Ose, William Insull, Santiago Campodonico, Michael Stepanavage, Russell S. Scott, Mei X. Wu, Helmut G. Schrott, Michael Melino, Michael H. Davidson, Yale B. Mitchel, Donald B. Hunninghake, Michele Mercuri, Ivan D. Escobar, Ann C. Tate, Evan A. Stein
Publikováno v:
Clinical Cardiology. 23:39-46
Background: Elevated levels of low-density lipoprotein (LDL) cholesterol promote the development of atherosclerosis and coronary heart disease. Hypothesis: Simvastatin 80 mg/day will be more effective than simvastatin 40 mg/day at reducing LDL choles
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::36999fc3cb5ed8d4609cc0e8cf654614
https://doi.org/10.1002/clc.4960230108
https://doi.org/10.1002/clc.4960230108
Autor:
Yale B. Mitchel, Evan A. Stein, Stuart R. Weiss, Helmut G. Schrott, Michael Stepanavage, Harold E. Bays, Carlos A. Dujovne, Michael Melino, Adrian S. Dobs, Michael H. Davidson
Publikováno v:
The American Journal of Cardiology. 82:311-316
This randomized, multicenter, double-blind parallel-group study was performed to evaluate the lipid-altering efficacy and safety of simvastatin 80 mg/day, a dose twice the current maximum recommended dose. At 20 centers in the United States, 521 male
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::835538f3cf203d2856ee0aab7b39967e
https://doi.org/10.1016/s0002-9149(98)00421-4
https://doi.org/10.1016/s0002-9149(98)00421-4
Autor:
Timothy Mant, Timothy V Olah, Michael Stepanavage, Johanna Wittreich, Haiyung Cheng, Barry J. Gertz, Mark Edwards, David G. Sciberras, Polvino William J
Publikováno v:
British Journal of Clinical Pharmacology. 43:49-54
Aim We evaluated the pharmacokinetics and pharmacodynamics of oral MK-462 in comparison with oral sumatriptan in healthy male volunteers. Methods Sixteen healthy male volunteers were studied in a rising, single dose, alternating panel design with eig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b07c0b17489e7ecde50bc26a4b8a13ef
https://doi.org/10.1111/j.1365-2125.1997.tb00137.x
https://doi.org/10.1111/j.1365-2125.1997.tb00137.x
Autor:
Kuang C. Yeh, Michael Stepanavage, Kristen Miller, Timothy J. Sullivan, Joyce D. King, Mary Scott, Kenneth Bachmann, Jules I. Schwartz, James H. Reese, Luis Jauregui
Publikováno v:
The Journal of Clinical Pharmacology. 35:529-535
The effects of famotidine (80 mg per day), cimetidine (1600 mg per day), and placebo on theophylline pharmacokinetic parameters in chronic obstructive pulmonary disease (COPD) patients were compared. This was an open-label, randomized, three-period c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8802be9b32974c0ac4a31301cdb59fe
https://doi.org/10.1002/j.1552-4604.1995.tb04100.x
https://doi.org/10.1002/j.1552-4604.1995.tb04100.x
Autor:
Christopher P, Cannon, Sukrut, Shah, Hayes M, Dansky, Michael, Davidson, Eliot A, Brinton, Antonio M, Gotto, Michael, Stepanavage, Sherry Xueyu, Liu, Patrice, Gibbons, Tanya B, Ashraf, Jennifer, Zafarino, Yale, Mitchel, Philip, Barter, T O, Wahl
Publikováno v:
The New England journal of medicine
Background Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-density lipoprotein (HDL) cholesterol and reduces low-density lipoprotein (LDL) cholesterol. Methods We conducted a randomized, double-blind, placebo-controlled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e855b6b1304ce1cdd2a9761a1949beac
https://pubmed.ncbi.nlm.nih.gov/21218559
https://pubmed.ncbi.nlm.nih.gov/21218559
Autor:
Eugene Braunwald, Yuliya Lokhnygina, Carolyn H. McCabe, Michael Stepanavage, Richard C. Pasternak, Christopher P. Cannon, Michael A. Blazing, Robert P. Giugliano, Thomas Musliner, Robert A. Harrington, Robert M. Califf
Publikováno v:
American heart journal. 159(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::060cdc83e00b0c2fb3c8ed9d0784cfb2
https://pubmed.ncbi.nlm.nih.gov/20435175
https://pubmed.ncbi.nlm.nih.gov/20435175
Autor:
Jonathan C. Cohen, Thomas Musliner, Manisha Chandalia, Helen H. Hobbs, Fang Xu, Susan G. Lakoski, Michael Stepanavage, Chun Lam, Scott M. Grundy, Gloria Lena Vega, Robert S. Lowe
Publikováno v:
The Journal of clinical endocrinology and metabolism. 95(2)
The level and duration of exposure to circulating low-density lipoprotein-cholesterol (LDL-C) are major contributors to coronary atherosclerosis. Therefore, optimal prevention will require long-term LDL-C reduction, making it important to select the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5819b31da30fd7e6969e8416b3c542c8
https://pubmed.ncbi.nlm.nih.gov/19965915
https://pubmed.ncbi.nlm.nih.gov/19965915